Group 1: Drug Pricing Agreements - President Trump announced "historic" drug pricing agreements with nine major pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Merck, aimed at reducing prices for Medicaid and direct-to-consumer sales through TrumpRx.gov [2][3] - The agreements are intended to align U.S. drug costs with the lowest prices paid by other developed nations, a concept known as "most-favored-nation" pricing [2] Group 2: Market Reactions to Drug Pricing - Despite the price cuts, pharmaceutical stocks saw gains, with GSK rising 1%, Merck gaining 1%, and Gilead Sciences surging approximately 3% [3] - The rally in stock prices is attributed to tariff exemptions secured by these companies in exchange for their pricing agreements, which alleviated potential tariff burdens [3][4] Group 3: Tariff Impacts - The U.S. effective tariff rate increased from 2.4% to 16.8%, the highest since 1935, contradicting claims that tariffs would reduce costs [5] - Market reactions to tariff announcements have been volatile, with significant drops in major indices following threats of tariff increases, such as a 2.7% decline in the S&P 500 on October 11, 2025 [6][8] Group 4: Economic Analysis of Tariffs - Analysts from Goldman Sachs warned that increased tariffs could significantly impact growth, estimating a reduction of nearly 0.7 percentage points from China's growth in 2025 [8] - The Tax Foundation labeled Trump's tariffs as the "largest tax hike since 1993," estimating an average increase of $1,100 per U.S. household in 2025 [8] Group 5: Warrior Dividend Announcement - President Trump announced a "$1,776 'warrior dividend'" for U.S. military personnel, funded by tariffs, totaling an estimated $2.6 billion [9][10] - Reports clarified that these payments were not new funds from tariffs but repurposed from existing military housing supplements, indicating a rebranding of existing funds rather than a new financial initiative [10][11] Group 6: Overall Economic Environment - The unpredictable nature of Trump's economic policies has led to erratic market behavior, with investors needing to navigate through rhetoric and actual economic impacts [12] - The combination of drug pricing agreements, tariff threats, and the warrior dividend illustrates the complex interplay of policy and market reactions in the current economic landscape [12]

Market Trends - The market rotation trend is shifting from mega-cap tech stocks towards small caps, cyclicals, and financials, with expectations for this trend to continue due to easy monetary policy from the Fed and upcoming rate cuts [2][3] - Small caps are viewed as undervalued and are expected to outperform as the Fed enters a rate-cutting cycle, supported by fiscal policies and a new tax bill that benefits R&D intensive small caps [2][3] Investment Methodology - A list of small cap stocks was created using stock screeners, focusing on those with high analyst upside potential and hedge fund interest, with data sourced from Insider Monkey's database [6][7] - The methodology aims to identify stocks that hedge funds are investing in, as this strategy has historically outperformed the market [7] Company Highlights UP Fintech Holding Ltd. (NASDAQ:TIGR) - UP Fintech Holding Ltd. has a market cap of $1.54 billion and an analyst upside of 72.79%, with 18 hedge fund holders [8][9] - The company reported a fiscal Q3 revenue of $175.2 million, reflecting a 73.3% year-over-year growth, and a net income of $53.8 million, up 29.9% quarter-over-quarter [12] - Despite strong fiscal results, analysts maintain a cautious outlook due to anticipated rate cuts, slowing client acquisition, and market volatility [10][11] Vericel Corporation (NASDAQ:VCEL) - Vericel Corporation has a market cap of $1.84 billion and an analyst upside of 53.33%, also with 18 hedge fund holders [14] - The company reported fiscal Q3 revenue of $67.5 million, an increase from $57.9 million in the prior year, with net product revenue driven by MACI and Epicel products [15] - Vericel reaffirmed its full-year revenue guidance of $272 to $276 million, with a projected growth rate for MACI in the low 20% range [17]

They're growing month over month. I mean, if you look at some of the public reports, their revenue has been increasing by billion dollars ARR every single month. And so, as they continue to grow, they need additional compute to keep up with the demand of their users.And so, they're one of the fastest growing companies in the world right now. >> How important was it that Google backs stopped all this. >> Critical.I mean, without Google, we would not be able to get JP Morgan and Goldman Sachs to commit the ba ...

AI & Data Center Investment - AI 和数据中心建设领域在经历了一段困难时期后，可能迎来转机，资金可能重新流入 [1][2][9] - 市场对超大规模企业（hyperscalers）雄心勃勃的扩张计划态度转变，此前这些计划曾备受华尔街赞誉，但现在因过度支出而受到惩罚 [4] - 行业内存在“懒人交易”或“循环交易”的现象，即一家公司给另一家公司资金，然后后者购买前者的产品，这可能隐藏了潜在的弱点 [12] - Oracle 获得了 OpenAI 价值 3000 亿美元的订单，以及来自其他公司的 2230 亿美元订单，这些潜在收入被计入剩余履约义务（RPO）[14][15] - OpenAI 可能会以超过 5000 亿美元，甚至高达 8300 亿美元的估值筹集 1000 亿美元资金 [20] - 如果 OpenAI 能够成功筹集大量资金（如 1000 亿美元），那么包括 Vertiv、Caterpillar、Core 和 Broadcom 在内的数据中心股票可能会再次上涨 [22][25] Market Trends & Opportunities - 消费者支出复苏，零售业和与可选消费相关的行业表现强劲，例如 Carnival Cruise 的股票上涨了近 10 个点 [4][5] - 金融股因 IPO 和收购活动而受到追捧，高盛（Goldman Sachs）今年上涨了 56%，超过了“七巨头”（Magnificent 7）中的大多数 [6] - 投机性股票，如量子计算、核能、资本不足的数据中心建设者、虚假的比特币延伸和替代能源公司，已经不再流行 [8] Company Specific Analysis - 报告对 Dell 的股票表示担忧，认为其零部件成本上升可能会影响利润，但同时指出公司内部人士正在买入股票，可能预示着股价不会大幅下跌 [26][27] - 报告对 Chewy 表示认可，认为其产品线质量高，价格合理，客户服务出色，但同时也承认该公司面临来自亚马逊的竞争压力 [30][31][32]

Despite pressure from the administration, a rough start to the year, biotech has seen a rebound this year. Our next guest is betting that that recovery will continue into 2026. So joining us now, Salivine Richtor.She is the lead US biotech analyst at Goldman Sachs Research. And Salivine, it's great to have you on the show. Welcome.>> Thank you for having me. What's interesting to me is that these names of these, you know, these stocks of these pharma companies that did inc this deal with the president just ...

Core Viewpoint - Market frustration with the November Consumer Price Index (CPI) is centered on the trustworthiness of the reported inflation figure, which showed a decrease to 2.7% from 3% in September, rather than the actual low inflation rate itself [1][2]. Group 1: CPI and Inflation Analysis - The annual CPI inflation slowed to 2.7% in November, reinforcing President Trump's narrative that inflation is "essentially gone" [1]. - Economists argue that the CPI figure was distorted due to the federal government shutdown, which halted data collection in October, leading to potentially misleading signals about underlying inflation trends [1][3]. - Shelter inflation, which includes rents and owners' equivalent rent (OER), accounts for about one-third of the CPI basket and significantly influenced the apparent cooling of inflation [2]. Group 2: Methodological Concerns - The Bureau of Labor Statistics (BLS) carried forward September price levels for October due to the lack of survey-based prices, effectively assuming zero inflation for that month, which compressed shelter price increases in November [3][4]. - Goldman Sachs chief economist Jan Hatzius noted that this methodology likely understated true shelter inflation, as the November increase reflects an average of price changes since May [4][5]. - Hatzius indicated that the same methodological choices that depressed November inflation could lead to artificial rebounds in future CPI readings, particularly in April [5]. Group 3: Expert Opinions - Omair Sharif, founder of Inflation Insights, criticized the BLS approach as "totally inexcusable," arguing that the shelter numbers only make sense if October inflation is considered zero [6].

Tokenized Asset Processing - Canton Network processes $6 trillion in tokenized assets for major financial institutions including Goldman Sachs, BNP Paribas, and Citadel Securities [1] - DTCC received SEC approval on December 17 to tokenize $100 trillion using Canton infrastructure [1] Market Valuation and Network Usage - Token trades at $3 billion fully diluted valuation (FDV) [1] - The network processes 120 times more value than its market capitalization suggests [1] Revenue Generation - Validators are earning $9 million monthly from network fees alone at current usage levels [1]

Core Insights - Neural Concept has raised $100 million in Series C funding led by Goldman Sachs Alternatives, highlighting the growing demand for enterprise AI in engineering [1][3][6] - The company is focused on redefining engineering workflows through CAD-native AI, enabling faster product development and reducing costly late-stage changes [2][5] - Neural Concept's technology is positioned as a leader in AI-native engineering, with significant growth across various industries including automotive, aerospace, and energy [3][4][9] Company Overview - Founded in 2019, Neural Concept provides an AI-first engineering platform that integrates AI into design and simulation workflows, significantly compressing development cycles [7][8] - The platform has demonstrated the ability to save customers $50 million annually, reduce late-stage redesigns by 30-50%, and accelerate time to market by up to two years [9] - The company has experienced a fourfold increase in enterprise revenue over the past 18 months and serves over 50 global companies, including major players like General Motors and General Electric [9] Future Plans - The new funding will be utilized to accelerate product development, including the launch of a generative CAD capability in early 2026, and to expand global go-to-market teams [5][6] - Neural Concept aims to deepen partnerships with industry leaders such as Nvidia, Siemens, and Microsoft, reinforcing its position as the intelligence layer across engineering systems [5][6]

Core Insights - The article discusses the positive outlook for international stocks in 2026, highlighting robust earnings, economic growth, and attractive valuations compared to the S&P 500 [2] - It emphasizes the potential for diversification away from the tech-heavy S&P 500, suggesting that international stocks are an appealing alternative for investors [2] Economic Context - Several international economies are expected to implement significant fiscal stimulus, which is anticipated to enhance stock market performance [3] - Germany's fiscal spending is projected to increase, with a focus on a €500 billion infrastructure fund and raising defense spending to 3.5% of GDP by 2029 [3] - Japan has announced its largest stimulus package since the pandemic, totaling ¥21.3 trillion (approximately $136 billion), aimed at inflation relief for key industries such as AI, semiconductors, and shipbuilding [4] Investment Methodology - The list of the 10 Best Non-US Stocks to Buy According to Hedge Funds was curated using the Finviz stock screener, WSJ, and Insider Monkey's Q3 2025 database [6] - Stocks were ranked based on the number of hedge fund holders, with market capitalization data sourced from the Wall Street Journal [6] Stock Highlights - **Shell plc (NYSE:SHEL)**: - Market Capitalization: $204.91 billion - Number of Hedge Fund Holders: 48 - Announced a final investment decision on its waterflood project at Kaikias field, expected to increase recoverable resource volumes by approximately 60 million metric barrels of oil equivalent [8][10] - Wall Street maintains a bullish outlook, with a Buy rating and a price target of £2,686.5 from Goldman Sachs and Barclays [12] - **Novo Nordisk A/S (NYSE:NVO)**: - Market Capitalization: $224.04 billion - Number of Hedge Fund Holders: 50 - Received a positive opinion from the European Medicines Agency for a higher dosage of Wegovy, showing improved weight loss results of around 20.7% at 72 weeks [14][15] - The stock has a cautious outlook from Wall Street, with a Hold rating and a price target increase from $47 to $54 by HSBC [17]

Core Insights - Avantor, Inc. has appointed Simon Dingemans to its Board of Directors, effective January 2, 2026, to enhance growth and profitability [1][3] Company Overview - Avantor is a leading global provider of mission-critical products and services to the life sciences and advanced technology industries, serving over 300,000 customer locations in 180 countries [5] Leadership Experience - Simon Dingemans has extensive global leadership experience, previously serving as CFO of GlaxoSmithKline plc, Partner at Goldman Sachs, and Managing Director at The Carlyle Group [2][4] - Dingemans currently holds board positions at Vodafone Group Plc and WPP plc, and has a strong background in operational transformation and financial discipline [2][4] Strategic Goals - The Board aims to accelerate growth and profitability at Avantor, with Dingemans' experience expected to support the Avantor Revival plan [3] - Dingemans expressed commitment to driving operational improvements and deepening customer partnerships for sustainable long-term success [3]